Publications by authors named "Karthik Chetlapalli"
Article Synopsis
- Iptacopan, a new oral medication approved by the FDA, targets paroxysmal nocturnal hemoglobinuria, a rare blood disorder, offering an alternative to existing intravenous treatments that can lead to persistent anemia.
- Recent phase 3 studies highlight its effectiveness as a standalone therapy compared to traditional complement C5 inhibitors.
- A comprehensive cost-effectiveness analysis revealed that iptacopan not only provided better quality-adjusted life years (QALYs) but also saved healthcare costs, making it a more favorable option over the standard-of-care in various countries, including Brazil, Japan, and the U.S.
Primary cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by cold-reactive antibodies that bind to red blood cells and lead to complement-mediated hemolysis. Patients with primary CAD experience the burden of increased health resource utilization and reduced quality of life. The standard-of-care (SOC) in patients with primary CAD has included cold avoidance, transfusion support, and chemoimmunotherapy.
View Article and Find Full Text PDFNeurons must establish and stabilize connections made with diverse targets, each with distinct demands and functional characteristics. At neuromuscular junctions (NMJs), synaptic strength remains stable in a manipulation that simultaneously induces hypo-innervation on one target and hyper-innervation on the other. However, the expression mechanisms that achieve this exquisite target-specific homeostatic control remain enigmatic.
View Article and Find Full Text PDF